Expert Highlights Caution for Chemo Substitutions for Gynecologic Cancers

Commentary
Video

Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.

Brian Slomovitz, MD, MS, FACOG, spoke with CancerNetwork® about the potential impact of substituting platinum-based chemotherapy for other platinum-based agents in the treatment of those with gynecologic cancers during the ongoing chemotherapy shortage in the United States.

Slomovitz, a gynecologic oncologist, director of Gynecologic Oncology, and co-chair of the Cancer Research Committee at Mount Sinai Medical Center in Miami Beach, Florida and a professor of Obstetrics and Gynecology at Florida International University, emphasized caution when making the decision to switch from carboplatin to cisplatin, or vice versa, as it is unclear how the change may impact patient outcomes or quality of life. He did note that the substitution does make sense in theory, but also stated it’s important to remember that they’re different agents.

Additionally, he spoke about how guidelines from organizations such as the Society of Gynecologic Oncology (SGO) may help in guiding treatment decision-making during the platinum-based chemotherapy shortages.

Transcript:

The quality of life definitely [is impacted] for a lot of perspectives, because the [adverse] effect profiles can be different and things like that. We've had to make some changes. We've written some consensus pieces on that, part of it with the Society of Gynecologic Oncology [SGO], which are nice guides of what to do in the setting. But there is some unknown. When we've studied thousands of patients for certain diseases like ovarian cancer with carboplatin, and then we say, ‘Hey, let's switch. Let's give cisplatin.’ Theoretically, it makes sense. But the bottom line is they're different drugs. I don't want to say to keep our fingers crossed; it's a little bit more scientific than that. But we're cautious that the efficacy is going to be the same.

Reference

SGO statement: carboplatin and cisplatin shortages. News release. Society of Gynecologic Oncology. April 21, 2023. Accessed August 7, 2023. https://tinyurl.com/y3dcmdk4

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.